liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Costs of bleeds relating to acute coronary syndrome therapies.
Universitaetsklinik der Universitat Witten/Herdecke, Wuppertal, Germany.
Hospital Pasteur, Nice, France.
Hospital Pasteur, Nice, France.
Hospital Parc Taulí, Sabadell, Spain.
Show others and affiliations
2010 (English)In: Journal of Medical Economics, ISSN 1369-6998, Vol. 13, no 2, 236-240 p.Article in journal (Refereed) Published
Abstract [en]

Objective: To estimate the costs to manage selected types of bleeding complications in patients with acute coronary syndrome (ACS) treated with antithrombotics, including antiplatelet, and fibrinolytic therapies: decrease in haemoglobin >3 g/dL, puncture site, and bleeding requiring transfusion of blood products.

Methods: Retrospective chart reviews of ACS patients experiencing decrease in Hb, puncture site, or bleeding requiring transfusion were conducted in hospitals in France, Germany, Italy, Spain and Sweden to determine the total length of stay (LOS), stay post-bleeding, procedures to identify the extent of bleeding, number and types of transfusion products, patient demographics, reason for hospital admission and disposition upon discharge. Country-specific costs were applied to estimate the average cost per patient by type of bleeding event.

Results: Records of 158 ACS patients with the bleeding complications were examined (26.9% decrease in Hb, 35.5% puncture site, and 37.8% transfusion). The average LOS was 10.6 days for decreasing Hb, 7.7 days for puncture site bleeding, and 11.3 days for patients receiving transfusions due to these bleeding events. The average costs per patient ranged between €3,986 and €10,252. The LOS ranged widely both within and across countries.

Limitations: The study has a small sample size and costs are confounded by co-morbidities.

Conclusions: The estimated costs for decreasing Hb, puncture site bleeding and bleeding resulting in transfusions provide a tool for researchers to conduct economic analyses of bleeding events associated with therapies for ACS.

 

Place, publisher, year, edition, pages
2010. Vol. 13, no 2, 236-240 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-67138DOI: 10.3111/13696998.2010.488882OAI: oai:DiVA.org:liu-67138DiVA: diva2:407692
Available from: 2011-03-31 Created: 2011-03-31 Last updated: 2017-02-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Janzon, Magnus

Search in DiVA

By author/editor
Janzon, Magnus
By organisation
CardiologyFaculty of Health SciencesDepartment of Cardiology in Linköping
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 109 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf